<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478826</url>
  </required_header>
  <id_info>
    <org_study_id>17-008088</org_study_id>
    <nct_id>NCT03478826</nct_id>
  </id_info>
  <brief_title>Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)</brief_title>
  <official_title>Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a repository of blood samples from patients with ILD to support future studies
      into the development of such biomarkers. Patients with pneumonia and healthy patients will
      also be recruited as a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed biospecimen repository would be derived from patients diagnosed with ILD. This
      is to include 500 patients in the repository, with each patient contributing one blood
      sample. Patients with pneumonia and healthy patients will also be recruited as a control
      group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Future Disease Management</measure>
    <time_frame>1 visit</time_frame>
    <description>Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>ILD</arm_group_label>
    <description>250 patients (male and females &gt;18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>100 healthy participants as a control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumonia</arm_group_label>
    <description>25 patients with pneumonia as a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ILD</intervention_name>
    <description>100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis</description>
    <arm_group_label>ILD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy</intervention_name>
    <description>100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.</description>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pneumonia</intervention_name>
    <description>100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.</description>
    <arm_group_label>Pneumonia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      To develop a repository of blood samples from patients with ILD to support future studies
      into the development of such biomarkers. Patients with pneumonia and healthy patients will
      also be recruited as a control group. The repository would be maintained in Dr. Carmona's
      laboratory in the Thoracic Diseases Research Unit in the Stabile building where all
      biospecimens will be stored.

      These samples will be stored in freezers in Dr. Carmona's laboratory space in the Thoracic
      Diseases Research Unit in the Stabile building for future research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of ILD or any fibrotic disease of the lung. A diagnosis of
        pneumonia and healthy volunteers will also be included as a control group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of
             pneumonia

          -  Patients willing to provide written informed consent

        Exclusion Criteria:

          -  Unwillingness/unable to give blood samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tami Krpata</last_name>
    <phone>507-538-1979</phone>
    <email>krpata.tami@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boleyn Andrist</last_name>
      <phone>507-284-9946</phone>
      <email>andrist.boleyn@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Eva Carmona, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eva M. Carmona Porquera</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>ILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD will not be shared at this time, but it may be possible that in the future outside institutions or other researchers within the Mayo Clinic may ask for specimen samples. If a specimen sample is requested, a new protocol will be submitted to the IRB or the IRB application for this study will be amended.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

